HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. doi:10.1002/ijc.2551621351269
   PubMed Web of Science ®Google Scholar
• Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–110. doi:10.1093/carcin/bgp26319934210
   PubMed Web of Science ®Google Scholar
• Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol. 2006;5(1):16–24.16531960
   PubMedGoogle Scholar
• Wellik DM. Hox genes and vertebrate axial pattern. Curr Top Dev Biol. 2009;88:257–278. doi:10.1016/S0070-2153(09)88009-519651308
   PubMed Web of Science ®Google Scholar
• Shah N, Sukumar S. The hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010;10(5):361–371. doi:10.1038/nrc282620357775
   PubMed Web of Science ®Google Scholar
• Thorsteinsdottir U, Sauvageau G, Hough MR, et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol. 1997;17(1):495–505. doi:10.1128/mcb.17.1.4958972230
   PubMed Web of Science ®Google Scholar
• Abe M, Hamada J, Takahashi O, et al. Disordered expression of HOX genes in human non-small cell lung cancer. Oncol Rep. 2006;15(4):797–802. doi:10.3892/or.15.4.79716525661
   PubMed Web of Science ®Google Scholar
• Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015–3024. doi:10.1200/JCO.2007.15.716418565887
   PubMed Web of Science ®Google Scholar
• Cheng W, Jiang Y, Liu C, Shen O, Tang W, Wang X. Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer. J Cancer Res Clin Oncol. 2010;136(8):1221–1227. doi:10.1007/s00432-010-0772-420151152
   PubMed Web of Science ®Google Scholar
• Yamatoji M, Kasamatsu A, Yamano Y, et al. State of homeobox A10 expression as a putative prognostic marker for oral squamous cell carcinoma. Oncol Rep. 2010;23(1):61–67. doi:10.3892/or_0000060619956865
   PubMed Web of Science ®Google Scholar
• Lim JY, Yoon SO, Seol SY, et al. Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J Gastroenterol. 2013;19(41):7078–7088. doi:10.3748/wjg.v19.i41.707824222951
   PubMed Web of Science ®Google Scholar
• Han Y, Lu S, Wen YG, et al. Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer. Eur J Cell Biol. 2015;94(12):642–652. doi:10.1016/j.ejcb.2015.08.00426552644
   PubMed Web of Science ®Google Scholar
• Shen ZH, Zhao KM, Du T. HOXA10 promotes nasopharyngeal carcinoma cell proliferation and invasion via inducing the expression of ZIC2. Eur Rev Med Pharmacol Sci. 2017;21(5):945–952.28338202
   PubMed Web of Science ®Google Scholar
• Li B, Cao X, Weng C, et al. HoxA10 induces proliferation in human prostate carcinoma PC-3 cell line. Cell Biochem Biophys. 2014;70(2):1363–1368. doi:10.1007/s12013-014-0065-724951955
   PubMed Web of Science ®Google Scholar
• Carrera M, Bitu CC, de Oliveira CE, et al. HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(4):3613–3623.26097543
   PubMed Web of Science ®Google Scholar
• Chu MC, Selam FB, Taylor HS. HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther. 2004;3(6):568–572. doi:10.4161/cbt.3.6.84815044858
   PubMed Web of Science ®Google Scholar
• Cui XP, Qin CK, Zhang ZH, et al. HOXA10 promotes cell invasion and MMP-3 expression via TGFβ2-mediated activation of the p38 MAPK pathway in pancreatic cancer cells. Dig Dis Sci. 2014;59(7):1442–1451. doi:10.1007/s10620-014-3033-624464212
   PubMed Web of Science ®Google Scholar
• Quagliata L, Matter MS, Piscuoglio S, et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology. 2014;59(3):911–923. doi:10.1002/hep.2674024114970
   PubMed Web of Science ®Google Scholar
• Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y, Zhang K. Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma. Tumor Biol. 2012;33(6):2125–2134. doi:10.1007/s13277-012-0472-6
   PubMedGoogle Scholar
• Cillo C, Schiavo G, Cantile M, et al. The HOX gene network in hepatocellular carcinoma. Int J Cancer. 2011;129(11):2577–2587. doi:10.1002/ijc.2594121626505
   PubMed Web of Science ®Google Scholar
• Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010;396(1):85–89. doi:10.1016/j.bbrc.2010.02.15220494116
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008;133(4):612–626. doi:10.1016/j.cell.2008.03.02518485870
   PubMed Web of Science ®Google Scholar
• Juan LJ, Shia WJ, Chen MH, et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem. 2000;275(27):20436–20443. doi:10.1074/jbc.M00020220010777477
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8. doi:10.1038/ncb264123263379
   PubMed Web of Science ®Google Scholar
• Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83–96. doi:10.1038/nrc343023303139
   PubMed Web of Science ®Google Scholar
• Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res. 1998;18(1B):555–564.9568177
   PubMed Web of Science ®Google Scholar
• Raman V, Martensen SA, Reisman D, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature. 2000;405(6789):974–978. doi:10.1038/3501612510879542
   PubMed Web of Science ®Google Scholar
• Xie HJ, Noh JH, Kim JK, et al. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One. 2012;7(4):e34265. doi:10.1371/journal.pone.003426522496786
   PubMed Web of Science ®Google Scholar
• Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S, Qiu Y. Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. Faseb J. 2014;28(10):4265–4279. doi:10.1096/fj.14-25065424948597
   PubMed Web of Science ®Google Scholar
• Benson GV, Nguyen TH, Maas RL. The expression pattern of the murine Hoxa-10 gene and the sequence recognition of its homeodomain reveal specific properties of Abdominal B-like genes. Mol Cell Biol. 1995;15(3):1591–1601. doi:10.1128/mcb.15.3.15917862151
   PubMed Web of Science ®Google Scholar
• Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol Cell Biol. 2003;23(13):4713–4727. doi:10.1128/mcb.23.13.4713-4727.200312808109
   PubMed Web of Science ®Google Scholar
• Guardavaccaro D, Corrente G, Covone F, et al. Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol. 2000;20(5):1797–1815. doi:10.1128/mcb.20.5.1797-1815.200010669755
   PubMed Web of Science ®Google Scholar
• Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21(17):2613–2622. doi:10.1038/sj.onc.120535311965534
   PubMed Web of Science ®Google Scholar
• Ito A, Kawaguchi Y, Lai CH, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J. 2002;21(22):6236–6245. doi:10.1093/emboj/cdf61612426395
   PubMed Web of Science ®Google Scholar